Boston, MA · Founded 2025 · Privately Held (backing)
Operator of a biotechnology company intended to develop first-in-class precision medicines targeting previously undruggable cancer and serious disease targets. Antares Therapeutics is based in Boston, MA and was founded in 2025. It is valued at about $299 million as of Oct 2026, set by institutional fund marks. It has raised $177 million across 2 recorded rounds; the latest was a $30 million early-stage round in May 2025.
PMV mark · valuation
$299.0M
Oct 2026
Priced at
its early-stage round
Apr 2025
Total raised
$177.0M
Last round
Early Stage VC
May 2025
No prints on record
No secondary trades in Antares Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Antares Therapeutics stock.
